Literature DB >> 22613403

Signal transduction pathways and transcriptional mechanisms of ABCB1/Pgp-mediated multiple drug resistance in human cancer cells.

H Sui1, Z-Z Fan, Q Li.   

Abstract

Multiple drug resistance (MDR), defined as the ability of tumour cells to survive exposure to many chemotherapeutic agents, is a major cause of treatment failure in human cancers. The membrane transporter P-glycoprotein (Pgp, encoded by the ABCB1 [adenosine triphosphate-binding cassette, subfamily B, member 1] gene) is the main mechanism for decreased intracellular drug accumulation in human MDR cancer. ABCB1/Pgp-mediated MDR involves several signal transduction pathways and transcription factors. Activation of these signal transduction pathways influences the prognosis of MDR human cancer. Signalling pathways involved in ABCB1/Pgp-mediated MDR include the mitogen-activated protein kinase (MAPK), c-Jun NH(2)-terminal kinase (JNK), p38, cyclic adenosine monophosphate-dependent protein kinase, phosphatidylino sitol 3-kinase and protein kinase C signalling pathways. This review summarizes the biological characteristics, target points and signalling cascade mediators of these pathways. Drugs targeted against these pathways may provide new therapies for treatment of ABCB1/Pgp-mediated MDR.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22613403     DOI: 10.1177/147323001204000204

Source DB:  PubMed          Journal:  J Int Med Res        ISSN: 0300-0605            Impact factor:   1.671


  43 in total

1.  AQP5 silencing suppresses p38 MAPK signaling and improves drug resistance in colon cancer cells.

Authors:  Xiaoming Shi; Shengchun Wu; Yongbin Yang; Lei Tang; Yüexin Wang; Junjie Dong; Bonan Lü; Guangwei Jiang; Wei Zhao
Journal:  Tumour Biol       Date:  2014-04-23

2.  Integration and bioinformatics analysis of DNA-methylated genes associated with drug resistance in ovarian cancer.

Authors:  Bingbing Yan; Fuqiang Yin; Q I Wang; Wei Zhang; L I Li
Journal:  Oncol Lett       Date:  2016-05-18       Impact factor: 2.967

Review 3.  Disrupting P-glycoprotein function in clinical settings: what can we learn from the fundamental aspects of this transporter?

Authors:  Francisco S Chung; Jayson S Santiago; Miguel Francisco M De Jesus; Camille V Trinidad; Melvin Floyd E See
Journal:  Am J Cancer Res       Date:  2016-08-01       Impact factor: 6.166

4.  Long noncoding RNA expression profiles of the doxorubicin-resistant human osteosarcoma cell line MG63/DXR and its parental cell line MG63 as ascertained by microarray analysis.

Authors:  Kun-Peng Zhu; Chun-Lin Zhang; Guo-Qi Shen; Zhong-Sheng Zhu
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

5.  Effects of Jianpi Jiedu Recipe on reversion of P-glycoprotein-mediated multidrug resistance through COX-2 pathway in colorectal cancer.

Authors:  Hua Sui; Hui-rong Zhu; Jie Wu; Alexander Yu Nikitin; Jian-feng Cai; Zhong-ze Fan; Qi Li
Journal:  Chin J Integr Med       Date:  2013-04-01       Impact factor: 1.978

6.  Inhibition of Vav3 could reverse the drug resistance of gastric cancer cells by downregulating JNK signaling pathway.

Authors:  B Tan; Y Li; Q Zhao; L Fan; Y Liu; D Wang; X Zhao
Journal:  Cancer Gene Ther       Date:  2014-11-28       Impact factor: 5.987

7.  PIK3CA and PIK3CB silencing by RNAi reverse MDR and inhibit tumorigenic properties in human colorectal carcinoma.

Authors:  Shuhua Wu; Feifei Wen; Yangyang Li; Xiangqian Gao; Shuang He; Mengyao Liu; Xiangzhi Zhang; Dong Tian
Journal:  Tumour Biol       Date:  2016-01-08

Review 8.  Inhibition of the multidrug resistance P-glycoprotein: time for a change of strategy?

Authors:  Richard Callaghan; Frederick Luk; Mary Bebawy
Journal:  Drug Metab Dispos       Date:  2014-02-03       Impact factor: 3.922

9.  RANK-RANKL interactions are involved in cell adhesion-mediated drug resistance in multiple myeloma cell lines.

Authors:  Masanobu Tsubaki; Tomoya Takeda; Misako Yoshizumi; Emi Ueda; Tatsuki Itoh; Motohiro Imano; Takao Satou; Shozo Nishida
Journal:  Tumour Biol       Date:  2016-01-14

10.  Expression of c-Jun, p73, Casp9, and N-ras in thymic epithelial tumors: relationship with the current WHO classification systems.

Authors:  Yuqing Ma; Qiaoxin Li; Wenli Cui; Na Miao; Xia Liu; Wei Zhang; Chen Zhang; Jian Wang
Journal:  Diagn Pathol       Date:  2012-09-14       Impact factor: 2.644

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.